In a Parkinson’s disease model, pharmacological inhibition of RIPK1 mitigated mitochondrial morphological alterations and dysfunction in dopaminergic neurons, indicating the beneficial impact of blocking necroptosis on Parkinson’s disease and suggesting its potential for therapeutic target [205]. Here, RIPK1 is linked to Parkinson disease.